期刊文献+

2014年全球热门药物靶点分析——IL-6靶标药物 被引量:2

Analysis of Global Hot Drug Targets in 2014 —— IL-6-targeted Drugs
原文传递
导出
摘要 IL-6是一种多效性前炎症细胞因子,具有多种生物学活性,包括介导炎症反应、免疫反应等。随着对IL-6及其受体信号通路研究的不断深入,IL-6现已成为一个有效的治疗靶点,在炎症及自身免疫性疾病的治疗过程中发挥重要作用。采用文献调研、数据库检索、数据统计与分析等定性定量情报学研究方法,从研发阶段、适应证、临床及上市药物等方面对全球IL-6靶标药物的研发情况进行分析,旨在为我国免疫药物的研发提供参考。 Interleukin-6(IL-6) is a multifunctional pro-infl ammatory cytokine with a variety of biological activities, including regulatory effects on infl ammation and immune response. With more and more researches conducted on IL-6 and its receptor signaling pathway, IL-6 has become an effective therapeutic target for infl ammation and autoimmune diseases. In this paper, qualitative and quantitative intelligence research methods such as literature investigation, database retrieval, as well as statistics and data analysis have been used to analyze the global research and development of drugs targeting IL-6, including development stage, indications, clinical data and marketed drugs, so as to provide reference for RD of immune modulating drugs in China.
出处 《药学进展》 CAS 2015年第11期870-873,共4页 Progress in Pharmaceutical Sciences
关键词 白细胞介素-6 细胞因子 炎症 自身免疫性疾病 靶点 药物研发 IL-6 cytokine infl ammation autoimmune disease drug target drug research and development
  • 相关文献

参考文献3

二级参考文献40

  • 1王越,杨洁,高燕,牛文彦,姚智.卵巢癌细胞IL-6、IL-8及其受体表达的研究[J].免疫学杂志,2006,22(5):475-479. 被引量:16
  • 2Pflegerl P, Vesely P, Hantusch B, et al. Epidermal loss of JunB leads to a SLE phenolype due to hyper IL-6 signaling [J]. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106(48): 20423-20428.
  • 3Knupfer H, Preiss sIL-6R: more than an agonist? [J]. Immunol Cell biol, 2008, 86(1): 87-91.
  • 4Heinrich PC, Behrmann I, Muller-Newen G, et al. Interleukin-6-type cytokine signalling through the gpl30/Jak/STAT pathway [J]. Biochem J, 1998, 334 ( Pt 2): 297-314.
  • 5Novotnydiermayr V, Lin B, Gu L, et al. Modulation of the interleukin-6 receptor subunit glycoprotein 130 complex and its signaling by LMO4 interaction [J]. The Journal of biological chemistry, 2005, 280(13): 12747-12757.
  • 6Frey N, Grange S, Woodworth T. Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis [J]. J Clin Pharmacol, 2010, 50(7):754-766.
  • 7Jazayeri JA, Carroll GJ, Vernallis AB. Interleukin-6 subfamily cytokines and rheumatoid arthritis: role of antagonists [J]. Int Immunopharmacol, 10(1): 1-8.
  • 8Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor [J]. Rheumatology (Oxford, England), 2010, 49(1): 15-24.
  • 9Dienz O, Eaton SM, Bond JP, et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells [J]. J Exp Med, 2009, 206(1): 69-78.
  • 10Youinou P, Jamin C. The weight of interleukin-6 in B cell-related autoimmune disorders [J]. J Autoimmun, 2009, 32(3/4): 206-210.

共引文献187

同被引文献21

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部